BACKGROUND: Equivalence of laboratory tests over time is important for longitudinal studies. Even a small systematic difference (bias) can result in substantial misclassification.
Equivalence of laboratory measurements over time is of central importance for studies of trends in disease prevalence, incidence, and progression. Assay recalibration is especially crucial when a disease is defined categorically with biomarker concentrations above or below a certain cut point. Even a small amount of systematic difference can lead to substantial misclassification of disease (1) (2) (3) (4) (5) (6) (7) . Small differences (e.g., Ͻ10%) may have little impact on clinical decision making or classification of individuals with values far from a clinical cutoff. However, at the population level, small, systematic differences shift the entire distribution of a biomarker, resulting in biased estimates of prevalence and incidence. Large epidemiologic studies must carefully assess the recalibration and reproducibility of their biomarker measurements to ensure equivalence across study visits and accurate comparisons over time.
Leveraging previous experience in the laboratory recalibration of biomarkers in large epidemiologic studies (1, 2, 5, 8 -10 ) , we undertook recalibration of 8 key laboratory tests in the Atherosclerosis Risk in Communities (ARIC) 7 Study. The ARIC Study is a prospective cohort with Ͼ25 years of follow-up and 5 study visits during which blood samples were collected. Our objectives were (a) to assess the equivalence of different biomarker measurements across the 5 ARIC visits, focusing on those where there were changes in research laboratories, sample types, and/or measurement procedure; (b) to determine recalibration corrections for those analytes lacking equivalence; and (c) to assess trends in each analyte before and after recalibration. To illustrate the potential impact of laboratory measurement change on prevalence and incidence of an important chronic disease, we examined trends in estimated chronic kidney disease (CKD) prevalence as defined from creatinine concentrations before and after recalibration in this study population.
Methods

STUDY POPULATION
The ARIC Study is an ongoing community-based cohort of 15 792 adults who were enrolled between 1987 and 1989 from 4 communities in the United States (11 ) . Participants have been invited to 4 follow-up examinations (visits 2 through 5, which took place during 1990 -1992, 1993-1995, 1996 -1998, and 2011-2013, respectively) . An institutional review board at each site approved all procedures, and all study participants provided written informed consent.
We selected a subsample of participants for remeasurement of biomarkers in stored blood samples. Among participants who had plasma samples available at all 5 visits, 200 were selected by use of stratified random sampling within 16 strata on the basis of 5-year baseline age categories (45-49, 50 -54, 55-59, and 60 -65 years), sex, and race/ethnicity (white or black). The purpose of stratified random sampling was to have the distribution of these characteristics in the recalibration subsample broadly reflect that in the full ARIC cohort.
LABORATORY MEASUREMENT PROCEDURES
Eight analytes were included in the main recalibration study: creatinine, uric acid, glucose, total cholesterol, HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), triglycerides, and high-sensitivity C-reactive protein (hs-CRP). Analytes were originally measured in the entire cohort at each of the 5 visits, except for creatinine and uric acid, which were not measured at visit 3, and hs-CRP, which was not measured at visits 1 or 3. Seven additional analytes that were not remeasured at all 5 study visits were also included in a secondary recalibration study: alanine aminotransferase, aspartate aminotransferase, ␥-glutamyl transpeptidase, N-terminal probrain natriuretic peptide, high-sensitivity cardiac troponin T, ␤ 2 -microglobulin, and ␤-trace protein (for details, see the Supplemental Data, which accompanies the online version of this article at http://www.clinchem.org/ content/vol61/issue7).
Analytes were reassayed at Baylor College of Medicine during 2011-2013 (Fig. 1) . For each of the 200 participants in the recalibration subsample, measurements were obtained from stored samples from all 5 visits. Samples had been stored at Ϫ70°C since original collection, which took place during visits from 1987 to 2013. LDL-C was calculated from the concentrations of total cholesterol, HDL-C, and triglycerides by the Friedewald formula. (See online Supplemental Table 1 for a detailed description of assay methodologies and approaches.) When available, commutable certified reference materials were included with some of the assays to Note that this schematic is an example, and details may vary by analyte. (See online Supplemental Table 1 for methods and assays used for each analyte.) UMN, University of Minnesota.
verify the traceability of measurement results to certified values of current high-quality reference materials (see online Supplemental Table 2 ).
STATISTICAL ANALYSIS
All statistical analyses were conducted with Stata version 13.0 (StataCorp).
Recalibration. For each analyte reassayed in the recalibration subsample, we calculated descriptive statistics for the original value, the reassayed value (in 2011-2013), and the difference of the 2 values. We calculated the bias for each analyte as bias (%) ϭ ͉mean of original value Ϫ mean of reassayed value͉ Ϭ mean of reassayed value.
We recalibrated all previous measurement values to the most recent results of measurement procedures performed in 2011-2013. Scatterplots were used to visually compare measurement values. To remove outliers that were extraneous to the recalibration process, we used an iterative outlier removal process. This approach is based on the assumption that outliers (defined as differences Ͼ3 SDs from the mean difference) are likely due to a nonanalytic error-related process, such as isolated sample degradation or data entry error, which would not be relevant to the recalibration. Briefly, observations Ͼ3 SDs from the mean difference were defined as outliers and removed. We then calculated the new SD and mean in the new data set, and values Ͼ3 SDs away from the mean difference were excluded. This procedure was repeated until no outliers remained. After exclusion of outliers, we conducted Deming regression of the original vs reassayed measurement values (12, 13 ) . For analytes with differences Ͼ10%, recalibration equations were derived from the Deming regression coefficients.
Impact of recalibration.
We assessed trends in original values and recalibrated measurement values over time in the total study population, both unadjusted and adjusted for the following covariates: sex, race, study center, body mass index, diabetes (self-reported physician diagnosis or medication use), current smoking status (current vs former/never), and hypertension (diastolic blood pressure Ն90 mmHg, systolic blood pressure Ն140 mmHg, or antihypertensive use). We plotted the mean analyte value pre-and postrecalibration by age at each visit (unadjusted graphs), as well as the predicted residual from the regression of the analyte value on the aforementioned covariates against age at each visit (adjusted graphs). We obtained the intercept (centered at the mean age at visit 1, 54 years) and slope for the regression lines plotted for each analyte at each visit to enable quantitative comparison of trends over time across visits before and after recalibration.
We calculated estimated glomerular filtration rate (eGFR) (with both original and recalibrated values for creatinine) using the 2009 CKD Epidemiology Collaboration (CKD-EPI) creatinine equation, which requires use of creatinine measurements traceable to isotope dilution mass spectrometry (14 ) . We defined prevalent CKD (stage 3ϩ) as eGFR Ͻ60 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 and incident CKD (stage 3ϩ) at visits 2, 4, and 5 as eGFR
Ϫ1 with an eGFR decline of Ն25% since visit 1. We compared the prevalence of CKD at visits 1, 2, 4, and 5 pre-and postrecalibration by estimating the proportion of participants with eGFR Ͻ60 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 at each visit. For comparison, we also calculated the prevalence of CKD at each visit with creatinine values that were recalibrated without having identified and excluded outliers. We calculated a Data are mean (SD) or n (%). Three participants were missing hypertension status; 1 participant was missing prevalent coronary heart disease status; and 2 participants were missing education level. Hypertension is defined as diastolic blood pressure >90 mmHg, systolic blood pressure >140, or use of antihypertensive medication. Prevalent coronary heart disease is defined as history of myocardial infarction, myocardial infarction from electrocardiogram, heart/arterial surgery, coronary bypass, or angioplasty. In the entire ARIC cohort, 16 participants were missing smoking status; 80 were missing hypertension status; 344 were missing prevalent coronary heart disease status; and 27 were missing education level. the incidence rate of CKD among participants with no CKD at visit 1 who attended visit 2, again comparing results before and after recalibration. We also compared the results to recalibration in previous studies, which largely relied on statistical, rather than laboratory, recalibration. (We consider statistical recalibration to be recalibration on the basis of statistics, in a setting in which analytes were not remeasured, and laboratory recalibration to be recalibration on the basis of remeasurement of analytes.)
Results
BASELINE CHARACTERISTICS OF THE RECALIBRATION SUBSAMPLE
The distribution of age and sex in the 200-participant recalibration subsample was similar to that of the total ARIC cohort ( Table 1 ). The recalibration subsample consisted of fewer white participants than the entire ARIC cohort (63% and 73%, respectively). Because inclusion in the recalibration subsample required attendance at all study visits during the 25 years of follow-up, subsample participants tended to be healthier compared with the entire cohort. For example, at visit 1, participants in the subsample had a lower mean body mass index (26.9 vs 27.7 kg/m 2 in the entire cohort) and a lower prevalence of current smoking (19% vs 26%), hypertension (24% vs 35%), and coronary heart disease (2% vs 5%).
ESTIMATES OF BIAS IN ORIGINAL VALUES
Overall, 4.5% of paired measurement values were considered outliers and removed with iterative outlier removal (described above). After removal of these outliers, reassayed measurement values were highly correlated with original values (of 28 comparisons of the 8 analytes across multiple visits, 43% had Pearson r Ͼ 0.95 and 18% had r Ͼ 0.99). Bias was Ͻ10% for all analytes except creatinine and uric acid (Table 2) . Lipids, glucose, and hs-CRP measurement values showed the lowest overall percent bias. Creatinine had particularly high bias: 49%, 47%, and 13% at visits 1, 2, and 4, respectively. Comparisons of original and reassay methods for HDL-C revealed substantial differences. However, we do not recommend recalibration of HDL-C across visits in the ARIC Study, because the method used to conduct assays at the most recent visit in 2011-13 (visit 5) and within the recalibration subsample was a direct enzymatic method, which differs substantially from magnesium dextran precipitation methodology used during visits 1-4 (see online Supplemental Table 1 ).
DEVELOPMENT AND APPLICATION OF RECALIBRATION EQUATIONS
On the basis of descriptive statistics of original and new measurement values and Deming regression results (Table 2 and online Supplemental Table 3 ), we developed recalibration equations for creatinine and uric acid at visits 1, 2, and 4. Recalibration equations were applied to the values in the entire cohort (Table 2 and online Supplemental Table 4 ).
RECALIBRATION EFFECTS ON eGFR TRAJECTORIES
Trends in eGFR over time were substantially better aligned after recalibration equations were applied to the entire cohort (Fig. 2, A through D) . The intercepts and slopes from the regression of mean eGFR on age by visit (centered at the mean age at visit 1, 54 years) were more similar after recalibration. Intercepts ranged from 101.4 to 163.0 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 before recalibration and 144.2 to 158.4 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 after recalibration; slopes ranged from Ϫ0.6 to Ϫ1.1 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 per year of age before recalibration and were nearly identical across visits at Ϫ1.0 mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 per year of age after recalibration (Table 3) . Similarly, trends in uric acid were improved after the recalibration equations were applied to the entire cohort (Fig. 2, E-H; Table 3 ). Ad- Fig. 2 . Regression of eGFR and uric acid versus age across 5 ARIC visits before and after applying the laboratory recalibration.
To examine trends versus age across visit, the lines plotted are creatinine-based eGFR (A, original values, unadjusted; B, recalibrated, unadjusted; C, original values, adjusted; D, recalibrated, adjusted) and uric acid (E, original values, unadjusted; F, recalibrated, unadjusted; G, original values, adjusted; H, recalibrated, adjusted) regressed on age (separately for each visit). Adjusted analyses included adjustment for sex, race, study center, body mass index, diabetes (self-reported physician diagnosis or medication use), current smoking status (current versus former/never), and hypertension (diastolic blood pressure ≥90 mmHg, systolic blood pressure ≥140 mmHg, or antihypertensive use). Recalibration allows us to remove differences in methodologic issues to the best of our ability, and differences that remain are largely due to changes over time.
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ditional results are shown in online Supplemental Table 5.
RECALIBRATION EFFECTS ON CKD PREVALENCE AND INCIDENCE
Compared with the prevalence of CKD determined by eGFR from original values for creatinine at visits 1, 2, 4, and 5 (21.7%, 36.1%, 3.5%, and 29.4%, respectively), the prevalence of CKD from recalibrated creatinine at these same visits was 1.3%, 2.2%, 6.4%, and 29.4%. In comparison, statistical recalibration in previous articles yielded prevalences of 1.9%, 3.6%, and 6.8% for visits 1, 2, and 4 (Fig. 3) . If we had recalibrated creatinine without removing any outliers, the prevalence estimates for CKD at each visit would have been higher than obtained with either the current recalibration or the previous statistical recalibration: 8.5%, 3.4%, and 6.5% for visits 1, 2, and 4, respectively. Among the 12 228 participants with no CKD at baseline defined by eGFR calculated with either original or recalibrated creatinine values, 1157 and 1480 participants developed CKD with original values for creatinine and recalibrated creatinine, respectively. Among those who had no CKD at baseline and attended visit 2, the incidence rate of CKD was 7.1 and 8.9 per 1000 person-years, as defined by eGFR with original values for creatinine and recalibrated creatinine, respectively.
Discussion
This rigorously performed laboratory recalibration study of blood analytes measured at 5 study visits spanning approximately 25 years of data collection in the ARIC Study demonstrated that many measurements were equivalent over time and did not require recalibration. Correlations over time in values of remeasured analytes ranged from high to very high. We found substantial bias in 2 analytes (creatinine and uric acid), which we addressed by developing recalibration equations in a subsample and applying these recalibrations to the entire cohort. With CKD as an example, we demonstrated that assuming equivalence of measurement values across time without confirmation by a rigorous recalibration study can result in substantial under-or overestimates of prevalence and incidence of disease. Additionally, the assay method for HDL-C was different during visit 5, suggesting that comparison of HDL-C measurement values across visits in ARIC or other studies that include both a direct enzymatic and precipitation method has serious limitations. Although the direct HDL-C method did show good agreement with commutable certified reference materials in our study, the accuracy of direct measurement of HDL-C for risk classification has been called into question, especially in the setting of hypertriglyceridemia (15 ) . Alternatively, it is possible that HDL-C measurement values with the direct enzymatic method during the recalibration study were affected by long-term sample storage (Յ25 years), since all original lipid analyses were performed on either fresh (visits 1-4) or shortterm (Ͻ1 weeks) frozen samples (visit 5). There is a paucity of data on the effects of long-term sample storage on HDL-C measurement values by direct methods. For those analytes that did require recalibration, alignment of values across visits was achieved and will strengthen future longitudinal analyses in this cohort.
CKD was chosen as an important example because classification is based on laboratory assessment of an eGFR threshold, and accurate characterization of trajectories of eGFR is of direct clinical interest (16 -20 ) . The dramatic impact of creatinine recalibration on CKD estimates has been reported in previous studies (2, 4, 21 ) . CKD prevalence and incidence estimates before and after recalibration of creatinine can differ substantially. In our study, a naive calculation of eGFR with original values for creatinine resulted in a substantial overestimate of the baseline CKD prevalence and underestimate of the CKD incidence rate. Baseline eGFR values were higher at visit 1 after recalibrating creatinine. Because the definition of incident CKD required a Ն25% decline in eGFR since visit 1, a greater number of participants fulfilled these criteria after recalibration of creatinine. We noticed greater bias in creatinine at visits 1 and 2 when measurements were conducted in an era before the purposeful change in creatinine assay result traceability to isotope dilution reference measurement procedures (22 ) . Whereas the evaluation of creatinine equivalence over time should be routine in studies of CKD trends, it is particularly important in studies such as ours, which span a long time period. Creatinine assay recalibration is known to have changed, and interlaboratory reproducibility has improved dramatically over the past decade (23 ) .
Indirect statistical correction (as opposed to direct laboratory recalibration) may be implemented where reassay of analytes is not feasible. This method may be achieved by selecting a "healthy subset" of the study population, in which the mean value of the analyte of interest, adjusted for any potential confounders, would be expected to be constant over time. Any significant deviation in mean analyte concentration over time would then be considered artifactual, and recalibration on the basis of statistics would be achieved by normalizing to a particular reference year/time period. This technique has been successfully implemented in previous studies (5, 6 ) . Previous recalibration studies in ARIC were statistical in nature, rather than laboratory based (24, 25 ) . Indeed, a previous statistical correction was used by ARIC investigators to recalibrate serum creatinine, by adjusting the serum creatinine values from the ARIC study population to have the same age-, sex-, and race-adjusted means as recalibrated National Health and Nutrition Examination Survey data (24 ) . The magnitude and direction of this statistical correction was reasonably similar to our direct recalibration (CKD prevalence of 1.9%, 3.6%, and 6.8% at visits 1, 2, and 4 from previous statistical recalibration; compared to 21.7%, 36.1%, and 3.5% with original values; and 1.3%, 2.2%, and 6.4% with laboratory recalibration). In settings where laboratory recalibration may not be feasible, statistical recalibration can provide insight into the magnitude of bias and provide an approach to minimizing it. There were several key strengths of this study. First, ARIC enrolled nearly 16 000 participants, which enabled calculation of precise estimates of CKD prevalence and incidence before and after application of recalibration equations to the full cohort. Second, ARIC is an ongoing prospective cohort study, which currently has approximately 25 years of follow-up. To date, there have been 5 visits, which allowed for comparison of trends over time before and after recalibration. Finally, our design was efficient and is potentially generalizable to other cohort studies, for which there may be interest in conducting laboratory recalibration studies in a practical and cost-effective manner.
Our study had several limitations. We assumed that the recalibration equations derived from the subset of 200 participants included in the recalibration subsample applied to the entire ARIC study population. These 200 samples may not have covered the entire range of values for each analyte, and there may be instances, especially at very low or very high values, in which the recalibration is an under-or overcorrection. Nonetheless, we were able to demonstrate improved similarity of creatinine and uric acid measurement values across ARIC visits with this approach. Our approach also assumes that the biomarkers being measured were in fact stable at Ϫ70°C in the stored samples and that changes in measurement procedure results were not simply due to changes in the biomarker concentrations in the samples over time.
Recalibration of laboratory measures is a key concern for large epidemiologic studies, particularly when trends in disease prevalence and risk factors over long periods of time are of interest. Reasons for poor reproducibility of measurement values over time may include changes in laboratory measurement procedures, more subtle differences in preanalytical sample processing or laboratory technique, sample degradation during storage, sample evaporation due to poorly sealed vials, and/or use of different sample types. However, laboratory recalibration over time assumes that the analyte is stable at the storage conditions. High correlations and improvement after recalibration supports this assumption for all the analytes examined in the current study, but it is difficult to test for long storage periods. Although availability of follow-up data for many years can be a major strength of large cohort studies, ensuring equivalence of measurement values over a long duration of time is instrumental in achieving accurate analytic results. Periodic recalibration studies are required to determine if measurement values lack equivalence and to recommend appropriate corrections, if necessary. Traceability of values to stable references would be ideal. Whereas external high-quality reference measurement procedures or commutable reference materials are not available for all analytes, they can at least be recalibrated to an internal reference for within-study comparisons over time. The techniques we used were standard laboratory and statistical analytic methods, and we encourage their use in large epidemiologic studies.
